Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 1, 2006, Pages 38-45

  Rosenthal, David I ^a   Fuller, Clifton David ^b   Machtay, Mitchell ^c   Algazy, Kenneth M ^d   Meyer, Dan M ^g   Kaiser, Larry R ^d   Yardley, Denise A ^e   Loiacano, Megan E ^a   Carbone, David P ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Sarah Cannon Cancer Research Institute   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Continuous infusion; Non small cell lung cancer; Paclitaxel; Radiation therapy

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFECT; DYSPHAGIA; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; ODYNOPHAGIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247881865     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200601000-00009     Document Type: Article

References (59)

1. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
2. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003;66:119-126.
3. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136.
4. Robertson JM, Ten Haken RK, Hazuka MB, et al. Dose escalation for non-small-cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1079-1085.
5. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-1223.
6. Lagerwaard FJ, Senan S, van Meerbeeck JP, et al. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small-cell lung cancer? Radiother Oncol 2002;63:151-157.
7. Choy H, Shyr Y, Cmelak AJ, et al. Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. Cancer 2000;88:1336-1346.
8. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
9. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
10. Movsas B. Innovative treatment strategies in locally advanced and/or unresectable non-small-cell lung cancer. Cancer Control 2000;7:25-34.
11. Curran W, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621.
12. Choy H, Kim DW Akerley WL, et al. Combined modality therapy (CMT) using concurrent radiation therapy (RT) with paclitaxel based chemotherapeutic regimen in unresectable locally advanced nonsmall cell lung cancer (LANSCLC): long term follow up on three sequential multi-institutional prospective phase II trials. Proc Am Soc Clin Oncol 2003;22:638.
13. Bonomi P. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small-cell lung cancer. Chest 1998;113:13S-16S.
14. Akerley W, Choy H. Single-agent paclitaxel and radiation for non-small-cell lung cancer. Semin Radiat Oncol 1999;9:85-89.
15. Johnson DH, Chang AY, Ettinger DS, et al. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. Oncology (Huntingt) 1998;12:67-70.
16. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
17. Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-19.
18. Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec. 2001;1:195-211.
19. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-446.
20. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-smallcell lung cancer. Semin Oncol 1995;22:70-74.
21. Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 1998;16:635-641.
22. Geard CR, Jones JM, Schiff PB. Taxol and radiation. J Natl Cancer Inst Monogr 1993;15:89-94.
23. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-242.
24. Chen Y, Pandya K, Keng PC, et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 2003;9:969-975.
25. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997;15:317-329.
26. Zanelli GD, Quaia M, Robieux I, et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 1997;33:486-492.
27. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-1884.
28. Dowell JE, Sinard R, Yardley DA, et al. Seven-week continuousinfusion paclitaxel concurrent with radiation therapy for locally advanced non-small-cell lung and head and neck cancers. Semin Radiat Oncol 1999;9:97-101.
29. Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-1373.
30. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997;39:537-544.
31. Gordon GS, Vokes EE. Chemoradiation for locally advanced, unresectable NSCLC: new standard of care, emerging strategies. Oncology (Huntingt) 1999;13:1075-1088; discussion 1999;13:1091-1094.
32. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
33. Loprevite M, Favoni RE, de Cupis A, et al. Interaction between novel anticancer agents and radiation in non-small-cell lung cancer cell lines. Lung Cancer 2001;33:27-39.
34. Kim JS, Amorino GP, Pyo H, et al. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 2001;51:525-534.
35. Choy H, Pyo H, Kim JS, et al. Role of taxanes in the combined modality treatment of patients with locally advanced non-small-cell lung cancer. Expert Opin Pharmacother 2001;2:963-974.
36. Choy H, Yee L, Cole BF. Combined-modality therapy for advanced non-small-cell lung cancer: paclitaxel and thoracic irradiation. Semin Oncol. 1995;22:38-44.
37. Choy HCW, Scott CB, Bonomi P, Travis P, Haluschak J, Belani CP. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 2002;21:291a.
38. Lanni JS, Lowe SW, Licitra EJ, et al. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997;94:9679-9683.
39. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620-3626.
40. Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;97:458-465.
41. Dicker AP, Williams TL, Iliakis G, et al. Targeting angiogenic processes by combination low-dose Paclitaxel and radiation therapy. Am J Clin Oncol 2003;26:E45-E53.
42. Ganansia-Leymarie V, Bischoff P, Bergerat JP, et al. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Cancer Agents 2003;3:291-306.
43. Choy H, Rodriguez FF, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71:3774-3778.
44. Hornback NB, Shen RN, Sutton GP, et al. Synergistic cytotoxic and antitumor effects of irradiation and taxol on human HeLa cervix carcinoma and mouse B16 melanoma cells. In Vivo 1994;8:819-823.
45. Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 1994;29:559-564.
46. van Rijn J, van den Berg J, Meijer OW. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys 1995;33:635-639.
47. Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-710.
48. Niero A, Emiliani E, Monti G, et al. Paclitaxel and radiotherapy: sequence-dependent efficacy-a preclinical model. Clin Cancer Res 1999;5:2213-2222.
49. Belani CP. Incorporation of paclitaxel and carboplatin in combinedmodality therapy for locally advanced non-small-cell lung cancer. Semin Oncol 1999;26:44-54.
50. Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small-cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol 2002;12:40-45.
51. Singer JW, Shaffer S, Baker B, et al. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 2006;16:243-254.
52. Wilson L, Jordan MA. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J Chemother 2004;4(16 Suppl):83-85.
53. Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Clin Cancer Res 1998;4:1931-1936.
54. Rathmann J, Leopold KA, Rigas JR. Daily paclitaxel and thoracic radiation therapy for non-small-cell lung cancer: preliminary results. Semin Radiat Oncol 1999;9:130-135.
55. Lau D, Ryu J, Gandara D, et al. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small-cell lung cancer. Semin Radiat Oncol 1999;9:117-120.
56. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316-3322.
57. Bunn PA Jr., Kelly K. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Clin Lung Cancer 2000;1(2 Suppl.):S23-S28.
58. Cooney MM, Tserng KY, Makar V, et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 2006;55:295-300.
59. Goffin JR, Anderson IC, Supko JG, et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Clin Cancer Res 2006;11:3417-3424.